2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-167734
    Pemedolac 114716-16-4 98%
    Pemedolac (AY-30715) is a potent analgesic with significant pain-relief efficacy against chemically induced and inflammatory pain in animal models. Pemedolac displays a notable separation between analgesic effects and anti-inflammatory activity, achieving effective pain relief at much lower doses than those required for anti-inflammatory or gastric irritant effects. Pemedolac also shows low ulcerogenic potential, indicating a safer profile compared to standard NSAIDs while being utilized for the treatment of neurological, skin, and musculoskeletal disorders.
    Pemedolac
  • HY-167740
    Glycerophosphoinositol (lysine) 425642-33-7 98%
    Glycerophosphoinositol (GroPIns) lysine is a phospholipid metabolite that possesses anti-dandruff, anti-inflammatory, and anti-aging activities; it significantly suppresses UVB-induced PGE secretion in NHEK keratinocytes.
    Glycerophosphoinositol (lysine)
  • HY-167825
    Barakol 24506-68-1 98%
    Barakol is a major compound found in Cassia siamea. Barakol inhibits MMP-3 activity. Barakol potentiates the anti-metastatic effect of Doxorubicin (HY-15142). Barakol induces apoptosis, with ROS generation, increase in expression ratio of Bax/Bcl-2, and caspase-9 activation. Barakol has laxative, anxiolytic, CNS depressant, and antioxidant, anticancer effects.
    Barakol
  • HY-167845
    LD03-DEX 2102449-40-9 98%
    LD03-DEX is a precursor compound of dexamethasone (HY-14648) with immunosuppressive activity.
    LD03-DEX
  • HY-167852
    GX-585 2098540-08-8 98%
    GX-585 is a sulfonamide analog that acts as a Nav1.7 channel inhibitor, demonstrating analgesic activity in treating neuropathic pain and inflammation.
    GX-585
  • HY-167855
    MRS4833 2801627-78-9 98%
    MRS4833 (compound 15) is an orally active, potent, competitive P2Y14R antagonist with an of IC50 of 5.92 nM for hP2Y14R and an IC50 of 4.8 nM for mP2Y14R. MRS4833 reduces airway eosinophilia in a protease-mediated asthma model and reverses chronic neuropathic pain in a mouse CCI model.
    MRS4833
  • HY-167863
    Piritrexim isethionate 79483-69-5 98%
    Piritrexim isethionate (BW 301U isethionate) is a fat-soluble dihydrofolate reductase inhibitor with activity in the treatment of severe psoriasis. Piritrexim isethionate may be as effective as methotrexate in the treatment of severe psoriasis and may have less hepatotoxicity.
    Piritrexim isethionate
  • HY-167870
    Piceatannol 4'-O-glucoside 116181-54-5 98%
    Piceatannol 4'-O-glucoside is an antioxidant. Piceatannol 4'-O-glucoside is active against oxidation of the human LDL. Piceatannol 4'-O-glucoside can be isolated from Mexican Bamboo.
    Piceatannol 4'-O-glucoside
  • HY-167873
    Habenariol 216752-89-5 98%
    Habenariol is a substantial phenolic antioxidant activity that can be isolated from the freshwater orchid, Habenaria repens.
    Habenariol
  • HY-167877
    PS-166276 348089-57-6 98%
    PS-166276 is a highly potent and less cytotoxic inhibitor of p38. PS166276 has an IC50 of 28 nM at p38 kinase and 170 nM in the THP-1 TNFα assay.
    PS-166276
  • HY-167879
    (Rac)-NPD6433 895908-81-3 98%
    (Rac)-NPD6433 is a racemate of NPD6433. NPD6433 is a triazenyl indole with broad-spectrum activity against all screening fungal strains. NPD6433 targets the enoyl reductase domain of fatty acid synthase 1 (Fas1), covalently inhibiting its flavin mononucleotide-dependent NADPH-oxidation activity and arresting essential fatty acid biosynthesis.
    (Rac)-NPD6433
  • HY-167891
    GPD-1116 690690-72-3 98%
    GPD-1116 is an orally active Phosphodiesterase (PDE) 4 and PDE1 inhibitor. GPD-1116 can reduce smoke-induced apoptosis of lung cells. GPD-1116 is effective in several disease models in animals, including emphysema, acute lung injury, chronic obstructive pulmonary disease (COPD), asthma and pulmonary hypertension.
    GPD-1116
  • HY-167892
    DRF-8417 439903-56-7 98%
    DRF-8417, an oxazolidinone antibiotic, is active against Gram-positive and fastidious Gram-negative bacteria. DRF 8417 exhibits potent activity against Gram-positive pathogens with MIC50 and MIC90 values ranging from 0.06 to 1 mg/L.
    DRF-8417
  • HY-167903
    Tesimide 35423-09-7 98%
    Tesimide is an aryl/heteroarylidene pyridinedione that can be used as an anti-inflammatory agent.
    Tesimide
  • HY-167917
    Conjugated linoleic acid 121250-47-3
    Conjugated linoleic acid is a group of isomers of Linoleic acid (HY-N0729) containing conjugated double bonds. Conjugated linoleic acid is mainly derived from dairy products and ruminant meats. Conjugated linoleic acid exhibits various activities such as anti-carcinogenicity, immunomodulation, weight loss promotion, reduction of muscle damage, and alleviation of inflammatory responses. Conjugated linoleic acid can be used as a food additive.
    Conjugated linoleic acid
  • HY-167924
    Ono 3307 free base 76472-28-1 98%
    Ono 3307 Free base is a novel synthetic protease inhibitor that exhibits protective effects against acute pancreatitis by preventing hyperamylasemia and pancreatic edema. Ono 3307 Free base also inhibits the redistribution of lysosomal enzymes in acinar cells and mitigates lactic dehydrogenase discharge. Ono 3307 Free base effectively reduces cathepsin B leakage from lysosomes in a dose-dependent manner. Ono 3307 Free base is able to target trypsin (Ki=48 nM), thrombin (Ki=0.18 μM), plasma kallikrein (Ki=0.29 μM), plasmin (Ki=0.31 μM), pancreatic kallikrein (Ki=3.6 μM), and chymotrypsin (Ki=47 μM).
    Ono 3307 free base
  • HY-167926
    3-Bromo-4,5-dihydroxybenzoic acid methyl ester 65841-10-3 98%
    3-Bromo-4,5-dihydroxybenzoic acid methyl ester is a marine-derived natural product known for its biological activity, specifically showcasing antioxidant properties and potential therapeutic applications against oxidative stress-related diseases.
    3-Bromo-4,5-dihydroxybenzoic acid methyl ester
  • HY-167937
    Propyl-GSK-2793660 1613458-71-1 98%
    Propyl-GSK-2793660 (compound 1) is a irreversible and covalent DPP1 inhibitor. Propyl-GSK-2793660 can be used for the study of bronchiectasis.
    Propyl-GSK-2793660
  • HY-167939
    (R)-Bambuterol 788821-30-7 98%
    (R)-Bambuterol is a β2-receptor agonist with anti-asthmatic and colitis-improving activity. (R)-Bambuterol is indicated for the treatment of asthma and chronic obstructive pulmonary disease and has the advantage of a once-daily dosing and a favorable side effect profile. (R)-Bambuterol significantly reduced disease severity in a mouse model of colitis, more effectively than (RS)-Bambuterol or (S)-Bambuterol. (R)-Bambuterol can significantly reduce the levels of inflammatory cytokines and reduce the infiltration of macrophages in mice with colitis. (R)-Bambuterol also increases β2-adrenoceptor levels and reduces the expression of IL-6, IL-17 and other related proteins in colon tissue in a dose-dependent manner.
    (R)-Bambuterol
  • HY-168002
    MPO-IN-8 62578-87-4 98%
    MPO-IN-8 is an orally active myeloperoxidase (MPO) inhibitor. MPO-IN-8 can inhibit the generation of hypochlorous acid in neutrophils and the release of extracellular traps (NETosis). In mice with gouty arthritis, MPO-IN-8 can reduce swelling, lower peroxidase activity, and decrease IL-1β levels.
    MPO-IN-8
Cat. No. Product Name / Synonyms Application Reactivity